Also trades as: 0JW9.L (LSE) · $vol 0M
LITS NASDAQ
Lite Strategy, Inc.
1W: -2.5%
1M: -14.7%
3M: +21.9%
YTD: -24.7%
1Y: -40.2%
3Y: -78.7%
5Y: -97.4%
$1.16
+0.04 (+3.12%)
Weekly Expected Move ±8.7%
$1
$1
$1
$1
$1
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 3.44.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
5 relationships5
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2023-02-23
Earliest Filing
2025-09-04
Latest Filing
target: 2
customer: 1
acquirer: 1
partner: 1
Counterparties (Filed by LITS)
5 relationshipsCompanies named in LITS's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| MEI Pharma, Inc. | — | customer | Borrower seeking loans of Digital Currency or USD from Lender | 2025-09-04 | View |
| Aardvark Therapeutics, Inc. | AARD | acquirer | Purchased assets related to ME-344 from MEI Pharma, Inc. | 2024-10-25 | View |
| MEI Pharma, Inc. | MEIP | target | Sold assets related to ME-344 to Aardvark Therapeutics, Inc. | 2024-10-25 | View |
| Computershare, Inc. | CS | partner | Appointed as Rights Agent for the Rights Agreement | 2023-10-03 | View |
| Infinity Pharmaceuticals, Inc. | INFI | target | Target company in the merger agreement with MEI Pharma, Inc. | 2023-02-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-07-30 | Earnings Release; Exhibits | View | |
| 2026-07-24 | Regulation FD | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-02-17 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-02-12 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-12-30 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-12-05 | Changes in Registrant's Certifying Accountant; Financial Statements and Exhibits | View | |
| 2025-11-20 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-11-18 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-10-30 | Departure/Election of Directors; Appointment of Officers; Other Events; Financial Statements and Exh | View | |
| 2025-09-15 | Unregistered Sales of Equity Securities | View | |
| 2025-09-10 | Amendments to Articles of Incorporation or Bylaws; Regulation FD Disclosure; Financial Statements an | View | |
| 2025-09-04 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Financial Stateme | Agreement | View |
| 2025-08-06 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-08-05 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-07-30 | Unregistered Sales of Equity Securities | View | |
| 2025-07-22 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Unregistered | Agreement | View |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-07 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-02-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR